Technical Analysis for TCRX - TScan Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 9.03% | |
| Below Lower BB | Weakness | 9.03% | |
| Down 3 Days in a Row | Weakness | 9.03% | |
| Lower Bollinger Band Touch | Weakness | 9.03% |
| Alert | Time |
|---|---|
| Up 2 ATRs | about 20 hours ago |
| Rose Above 10 DMA | about 20 hours ago |
| 10 DMA Resistance | about 21 hours ago |
| Up 10% | about 21 hours ago |
| Rose Above Previous Day's High | about 21 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.69 |
| 52 Week Low | 3.73 |
| Average Volume | 199,750 |
| 200-Day Moving Average | 6.61 |
| 50-Day Moving Average | 5.36 |
| 20-Day Moving Average | 5.20 |
| 10-Day Moving Average | 4.93 |
| Average True Range | 0.28 |
| RSI (14) | 43.82 |
| ADX | 20.04 |
| +DI | 17.57 |
| -DI | 25.92 |
| Chandelier Exit (Long, 3 ATRs) | 4.85 |
| Chandelier Exit (Short, 3 ATRs) | 5.36 |
| Upper Bollinger Bands | 5.84 |
| Lower Bollinger Band | 4.56 |
| Percent B (%b) | 0.31 |
| BandWidth | 24.54 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.15 |
| MACD Histogram | -0.0425 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.79 | ||||
| Resistance 3 (R3) | 5.75 | 5.42 | 5.65 | ||
| Resistance 2 (R2) | 5.42 | 5.21 | 5.45 | 5.60 | |
| Resistance 1 (R1) | 5.19 | 5.08 | 5.31 | 5.23 | 5.56 |
| Pivot Point | 4.86 | 4.86 | 4.92 | 4.89 | 4.86 |
| Support 1 (S1) | 4.63 | 4.65 | 4.75 | 4.67 | 4.34 |
| Support 2 (S2) | 4.30 | 4.52 | 4.33 | 4.30 | |
| Support 3 (S3) | 4.07 | 4.30 | 4.25 | ||
| Support 4 (S4) | 4.11 |
